BLOSSOMHILL THERAPEUTICS


Associated tags: Drug discovery, OrbiMed

Locations: UNITED STATES, NORTH AMERICA, CALIFORNIA, TURNING POINT

BlossomHill Therapeutics Closes $100 Million Series B Financing

Retrieved on: 
Thursday, February 29, 2024
Research, FDA, Public Relations, Investor Relations, Communications, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, OrbiMed, Autoimmune disease, Intelligence, General partnership, Quality of life, Drug development, Drug design, Bristol Myers Squibb, Therapy, Life expectancy, Medicine, Patient, IND, Cancer, Pharmaceutical industry

BlossomHill Therapeutics, Inc. , a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the closing of a $100 million Series B financing round.

Key Points: 
  • BlossomHill Therapeutics, Inc. , a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the closing of a $100 million Series B financing round.
  • In conjunction with the financing round, Sundeep Agrawal, M.D., General Partner at Colt Ventures, and Timothy Stubbs, M.D., Principal at Vivo Capital, will join the BlossomHill Board of Directors.
  • This financing brings the total capital raised by the company to $173 million.
  • “We appreciate the strong support from our new and existing investors in this round of financing,” said J. Jean Cui, Ph.D., President and Chief Executive Officer of BlossomHill Therapeutics.

BlossomHill Therapeutics Chief Executive Officer, Jingrong Jean Cui, Ph.D., Elected to the National Academy of Engineering

Retrieved on: 
Wednesday, February 14, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Engineering, Manufacturing, Pfizer, Education, FDA, Crizotinib, National academy, Entrepreneurship, Bristol Myers Squibb, NAE, Therapy, Cancer, Pharmaceutical industry

BlossomHill Therapeutics , a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE).

Key Points: 
  • BlossomHill Therapeutics , a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced Jingrong Jean Cui, Ph.D., Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, has been elected to the National Academy of Engineering (NAE).
  • The prestigious honor recognizes Dr. Cui’s direct role in the innovation of new medicines to fight cancer and address urgent medical needs.
  • As Co-Founder, President and Chief Executive Officer of BlossomHill Therapeutics, Dr. Cui leads the effort to design the novel small molecule drug candidates in the company’s R&D pipeline.
  • Prior to BlossomHill, Dr. Cui co-founded Turning Point Therapeutics, Inc., which Bristol Myers Squibb acquired in June 2022 for $4.1 billion.